![]() | |
Names | |
---|---|
IUPAC name [6-(5-Chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] piperazine-1-carboxylate | |
Other names SEP-174559 | |
Identifiers | |
3D model (JSmol) | |
ChemSpider | |
EC Number |
|
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
| |
Properties | |
C16H15ClN6O3 | |
Molar mass | 374.79 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Desmethylzopiclone, also known as SEP-174559, is an active metabolite of the sedative-hypnotic drug zopiclone.
Unlike its parent compound, which is a largely non-selective benzodiazepine receptor agonist, desmethylzopiclone is a selective partial agonist at the benzodiazepine site of α3-containing GABA receptor subtypes. [1] It is also an antagonist to nicotinic acetylcholine receptors and NMDA receptors. [1]
Desmethylzopiclone has been described as a potential anxio-selective metabolite of zolpiclone owing to its selective affinity for the modulation of α3-containing GABA receptor subtypes. [1] Modulation of these GABAA subtypes have been implicated as key mediators of the anxiolytic effects of benzodiazepines. [2]
A method for the quantification of desmethylzopiclone from urine has been developed and may serve useful in forensic analysis of cases involving zolpiclone intoxication. [3]